• Cross-sectional study to compare glucose and lipid metabolism in SMI subjects treated with either Fanapt® (iloperidone), Zyprexa® (olanzapine), or Risperdal® (risperidone)
Researchers from the Massachusetts General Hospital, Psychiatry Department seek men and women ages 18-65 that have a diagnosis of schizophrenia, schizoaffective disorder, major depressive disorder, bipolar disorder, psychosis NOS, delusional disorder or paranoid disorder and are treated with either Fanapt® (iloperidone), Zyprexa® (olanzapine), or Risperdal® (risperidone). This two-month research study examines how these three antipsychotic medications affect glucose metabolism, or how the body breaks down sugar, in patients with serious mental illness. This study requires 3 research visits, which include an EKG, cognitive testing, a whole body x-ray, a nutritional assessment and a fasting blood draw. Participants are compensated up to $110. We may provide reimbursement for your travels or provide a cab voucher. If interested, please call Liana at (617) 912-7882 or email lpetruzzi@partners.org.
Institution  –  MGH - Massachusetts General Hospital, Boston, MA; Freedom Trail Clinic, Boston, MA
Principal Investigator  – David C Henderson, MD
  
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name  – Petruzzi J Liana, CRC
Phone  – 617 912 7882